Core Viewpoint - Weikang Pharmaceutical (300878) is expected to report a net loss attributable to shareholders of between 170 million to 245 million yuan for 2025, compared to a loss of 147 million yuan in the same period last year [2] Group 1: Financial Performance - The company's capacity utilization rate is low, leading to a provision for fixed asset impairment of 45.55 million yuan [2] - The decline in product sales prices and lower-than-expected sales volume have resulted in a decrease in both operating revenue and gross margin [2] - The company has also made a provision for inventory impairment of 30.39 million yuan due to some inventory nearing expiration [2] Group 2: Regulatory Developments - The company has recently received a drug registration certificate from the National Medical Products Administration for its product, Er Dong Tang Granules, which is used for lung and stomach relief [2]

报告期内，预计非经常性损益对公司归属于上市公司股东的净利润的影响约为1500万元，主要为政府补 助和理财收益等项目影响。上年同期，非经常性损益对归属于上市公司股东的净利润的影响金额为- -6.42亿元。 公告中提到，业绩变动的原因主要是由于行业政策与市场环境变化，部分产品的销量或价格下滑，导致 相关利润下降。此外，整体市场供需关系影响了部分中药材品种价格的延续下跌，使得公司的中药材业 务仍处于亏损状态。 近日，振东制药（300158）发布公告称，预计2025年度归母净利润约亏损2.2亿元至2.8亿元，较上年同 期亏损13.29亿元有所改善。 ...

Core Viewpoint - The A-share market experienced a mixed performance with the three major indices showing a decline by the end of the trading day, indicating a cautious sentiment among investors [1]. Market Performance - The Shanghai Composite Index closed at 4132.61 points, down by 0.09%, with a total trading volume of 14,518.60 billion yuan - The Shenzhen Component Index closed at 14,316.64 points, down by 0.85%, with a total trading volume of 17,963.43 billion yuan - The ChiNext Index closed at 3319.15 points, down by 0.91%, with a total trading volume of 8,384.91 billion yuan [1]. Sector Performance - The top-performing sectors included: - Precious metals with a notable increase - Oil and gas extraction and services, which rose by 4.71% - Small metals, which increased by 4.51% [2]. - The sectors that faced declines included: - Military electronics, which dropped by 5.42% - Military equipment, down by 3.71% - Semiconductor sector, which decreased by 3.00% [2].

2025年以来，北京同仁堂科技发展股份有限公司（以下简称"同仁堂科技公司"）大力推动重点科研项目攻关，在新药研发、上市品种临 床研究，以及学术论文发表、行业标准制定等相关领域接连步入新阶段。企业以市场需求为导向、以科研创新为驱动的发展模式频结硕 果，老字号中药企业的核心竞争力正从传统工艺向现代科研证据体系延伸。 同仁堂科技公司聚焦上市品种的持续深耕更是成果丰硕，多项针对名优品种的临床研究步入收获期。金匮肾气丸完成了针对"肾阳虚证夜 尿频多"的临床研究，为这一经典名方治疗特定症状提供了新的临床证据。感冒清热颗粒完成了治疗普通感冒（风寒证）的有效性和安全 性临床研究，进一步明确了其适用人群和疗效特点。此外，六味地黄类方治疗糖尿病视网膜病变的药效机制研究、永盛合阿胶治疗肿瘤 相关性贫血的真实世界研究等也已完成，系统揭示了传统方药在现代疾病治疗中的科学内涵。在基础研究层面，同仁堂科技公司对加味 逍遥丸、京制牛黄解毒片等品种的药效物质基础和作用机制研究取得关键突破，致力于"讲清楚、说明白"中药为什么有效。 从衡量企业科研实力的一个重要维度——高质量论文发表来看，15篇高水平论文发表，其中3篇为SCI论文，不仅展现了公司 ...

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Views - The report highlights the ongoing decline in the national population and birth rates, with a significant increase in the elderly population, which is expected to drive demand for home medical devices and supplies [5][21] - The report emphasizes the long-term positive trend in the innovative drug sector, supported by the strength of China's innovative drug companies in global competition [7] - The medical device sector is showing signs of improvement, with major companies reporting better performance in Q3, indicating a potential recovery in the industry [9] Summary by Relevant Sections Industry Overview - As of January 26, 2026, the closing index stands at 8623.36, with a 52-week high of 9323.49 and a low of 6876.88 [1] Recent Market Performance - During the week of January 19-23, 2026, the A-share pharmaceutical sector fell by 0.39%, outperforming the CSI 300 index by 0.23 percentage points but underperforming the ChiNext index by 0.05 percentage points [6][24] - The medical device sector is expected to attract more investment as the pressure from centralized procurement diminishes [9][30] Population and Demographics - By the end of 2025, the total population of China was 1,404.89 million, with a natural population growth rate of -2.41% [15] - The elderly population (aged 65 and above) reached 22,365 million, accounting for 15.9% of the total population, indicating a trend towards an aging society [18][20] Investment Recommendations - The report suggests focusing on companies in the elderly care medical sector, such as Yuyue Medical, Kefu Medical, and Loxin Medical, due to the anticipated increase in demand for home medical devices [5][22] - In the innovative drug sector, companies like Innovent Biologics and Kintor Pharmaceutical are highlighted as beneficiaries of the growing global participation of Chinese innovative drug firms [7][27] - For the medical device sector, companies such as Mindray and Hunan Aohua are recommended due to their improving performance and market position [9][30] Future Outlook - The report anticipates a recovery in the medical device sector as procurement policies become more reasonable and the pressure from centralized procurement decreases [30] - The innovative drug sector is expected to continue its upward trajectory, with more innovative projects anticipated in 2026 [26][28]

鲁南制药集团股份有限公司党委书记、董事长、总经理张贵民研究员代表依托单位致欢迎辞，向各位专 家和嘉宾的到来表示热烈欢迎，向各位专家和嘉宾长期以来对实验室建设的关心和支持表示感谢。 齐鲁晚报.齐鲁壹点通讯员范建伟 近日，经方与现代中药融合创新全国重点实验室第一届学术委员会第三次会议在北京召开。 专家代表对实验室获批以来的建设工作及研究进展给予了充分肯定，围绕实验室的发展目标、平台构 建、机制体制、成果转化等问题进行了深入讨论，并提出针对性意见和建议。 鲁南制药集团相关负责人表示，本次会议为经方与现代中药融合创新全国重点实验室在新阶段的发展明 确了方向、凝聚了共识、注入了动能。实验室将在学术委员会指导下，聚焦经方与现代中药创制的关键 科学问题和共性技术，打通科技链与产业链转化应用堵点，提升中药新药创制水平和研发效率，促进中 医药产业高质量发展，努力成为高效服务"健康中国"战略的科技力量。 实验室相关负责人从"实验室基本情况""研究进展与代表性成果""队伍建设与人才培养""运行管理与开 放交流"等四个方面，向与会专家汇报了实验室自批复建设以来的建设进展情况。 ...

截至发稿，马君累计任职时间13年148天，现任基金资产总规模508.95亿元，任职期间最佳基金回报 144.61%， 任职期间最差基金回报-75.62%。 数据显示，银华基金旗下1只基金重仓众生药业。中药（562390）四季度持有股数13.1万股，占基金净 值比例为3.2%，位居第十大重仓股。根据测算，今日浮盈赚取约16.38万元。 中药（562390）成立日期2022年7月20日，最新规模7769.73万。今年以来收益1.81%，同类排名 4593/5579；近一年收益2.61%，同类排名4183/4270；成立以来亏损2.85%。 中药（562390）基金经理为马君。 1月26日，众生药业涨5.81%，截至发稿，报22.78元/股，成交12.77亿元，换手率7.50%，总市值193.61 亿元。 资料显示，广东众生药业股份有限公司位于广东省东莞市石龙镇西湖工业区信息产业园，成立日期2001 年12月31日，上市日期2009年12月11日，公司主营业务涉及药品的研发、生产和销售。主营业务收入构 成为：中成药销售53.03%，化学药销售38.12%，中药材及中药饮片销售6.13%，原料药及中间体销售 2.14 ...

Group 1 - The core viewpoint of the news is that Te Yi Pharmaceutical (SZ002728) experienced a significant stock price increase due to strong performance forecasts and product demand, leading to a trading halt at a price of 13.19 yuan, with a 10.01% increase and a total market value of 6.767 billion yuan [1] Group 2 - The company forecasts a substantial net profit growth of 241.55%-339.13% for 2025, with a more pronounced growth in non-recurring net profit expected to reach 263.83%-371.64% [1] - In the first three quarters of 2025, the company reported a net profit increase of 985.18% and a non-recurring net profit increase of 2508.06%, alongside a revenue growth of 51.86%, indicating strong financial performance [1] - The core product, cough medicine, has seen significant sales growth, while other products like skin disease blood toxin pills and blood sugar-lowering pills show considerable market potential, contributing to revenue and profit expectations [1] - The company has optimized its marketing channels and successfully transitioned to a "self-operated + promotional service provider" model, enhancing product sales [1] - The traditional Chinese medicine sector has gained market attention recently, with other stocks in the sector also performing well, attracting capital inflow to Te Yi Pharmaceutical due to its outstanding performance [1] - Technical indicators suggest that if short-term moving averages show a bullish arrangement, it may attract more investors to buy [1]

Investment Rating - The industry maintains an "Overweight" rating [9] Core Views - The report highlights the performance of the traditional Chinese medicine (TCM) sector, noting a 0.89% increase in the TCM II index, making it the second-best performing sub-sector in the pharmaceutical industry [3] - The report emphasizes the importance of the 2025 performance outlook and the progress of the essential drug catalog adjustments, with many companies showing positive profit growth [6] - The report suggests that the TCM industry may continue to experience structural differentiation, with companies focusing on external markets and innovation to find new growth points [6] Market Performance - The TCM II index closed at 6406.83 points, up 0.89% for the week, while the overall pharmaceutical index fell by 0.39% [3] - The best-performing companies in the TCM sector included *ST Changyao, ST Xiangxue, and Fangsheng Pharmaceutical, while the worst performers included Zhenbaodao and Pianzaihuang [3] Valuation - The TCM sector's PE (ttm) was 27.34X, up 0.23X week-on-week, with a PB (lf) of 2.3X, also showing a slight increase [4] - The PE is at the 28.89% percentile since 2013, while the PB is at the 5.74% percentile [4] Raw Material Market - The TCM raw material index rose by 1.1% due to increased demand for tonic herbs and price hikes in certain materials [5] - The overall market for TCM materials remains volatile, with a notable increase in demand for tonic herbs [5] Investment Suggestions - The report recommends focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [7] - Specific investment targets include companies with strong R&D capabilities, those less affected by centralized procurement, and brands with strong market presence [13]

Core Insights - The article presents a summary of stock performance based on three testing strategies, highlighting a total of 15 stocks with an average dividend yield of 4.60% and an average price-to-earnings (P/E) ratio of 32.54 [1] Group 1: Stock Performance Summary - The intersection of the three strategies includes 15 stocks with an average dividend yield of 4.60% and an average P/E ratio of 32.54 [1] - The union of the three strategies results in 20 stocks with an average dividend yield of 4.76% and an average P/E ratio of 33.96, indicating a higher dividend yield compared to the previous period while the P/E ratio is lower [2][3] Group 2: High-Value Stocks - Jizhong Energy (000937) is a leading coal mining company with a P/E ratio of 48.51 and a high dividend yield of 10.89%, despite a significant drop in net profit [4] - Thinking Control (603508) specializes in railway safety equipment with a P/E ratio of 18.2 and a dividend yield of approximately 5.8%, showing a positive net profit growth [4] - Hangmin Co. (600987) is a leader in the dyeing industry with a low P/E ratio of 10.06 and a stable dividend yield of 3.23%, despite facing industry challenges [5] - Kemin Food (002661) is a leading noodle manufacturer with a P/E ratio of 15.2 and a dividend yield of about 4.8%, although it has experienced a decline in net profit [5] Group 3: Mid-Value Stocks - Zhongjian Vehicles (301039) is a global leader in commercial vehicles with a P/E ratio of 20.97 and a stable net profit despite a year-on-year decline [6] - Yabao Pharmaceutical (600351) is a leader in traditional Chinese medicine with a P/E ratio of 22.3 and a dividend yield of approximately 3.5%, showing stable cash flow [6] - Qianjiang Motorcycle (000913) is a major player in the motorcycle industry with a P/E ratio of 18.5 and a dividend yield of about 2.1%, facing market challenges [6] - Wufangzhai (603237) is a well-known brand in the rice dumpling market with a P/E ratio of 25.6 and a dividend yield of approximately 3.8%, despite a decline in net profit [6] Group 4: Cautious Stocks - Hengsheng Energy (605580) operates in the thermal power sector with a high P/E ratio of 61.83, indicating overvaluation concerns [7] - S Jiatong (600182) is in the tire industry with a P/E ratio of around 45 and a low dividend yield of 0.3%, facing profitability challenges [7] - Delmar (301332) is a small appliance company with a P/E ratio of about 40, showing weak brand strength compared to peers [7] - Wenfeng Co. (601010) is a retail company with a P/E ratio of about 22, experiencing a significant decline in net profit [7]